Autologous-HER2-specific-T-cells

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAutologous-HER2-specific-T-cells
Drug Alias NameAutologous-HER2-specific-T-cells
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 modulatorsT lymphocyte replacements
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsBrain NeoplasmsSarcoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesBaylor College Of Medicine
China Registration ClassN/A

Develop Information

Active CompaniesMethodist Hospital SystemTexas Children'S HospitalBaylor College Of Medicine
Inactive CompaniesN/A
Active IndicationsBrain NeoplasmsSarcoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A